Replicor to disclose interim REP 2055 clinical efficacy data in patients with chronic hepatitis B at the 46th meeting of the European Association for the Study of the Liver (EASL 2011).
March 30-April 3, 2011, Internationales Congress Centrum (ICC) Berlin, Germany
March 30, 2011 – Replicor will disclose updated interim results from its proof of concept clinical trial at the 46th meeting of the European Association for the Study of the Liver (EASL 2011) currently being held from March 30 – April 3. This is the largest annual meeting in Europe dedicated to treatment of liver disease which typically attracts thousands of physicians and researchers. This trial is examining the safety and efficacy of REP 2055 in human patients with chronic hepatitis B (HBV).
REP 2055 represents a new class of antiviral agent that blocks the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. REP 2055 has been previously shown to rapidly clear HBsAg in the serum of patients infected with HBV and appears to allow these patients to regain effective immunological control over their infection, resulting in sustained virologic responses after only 5-6 months of treatment. Replicor will present updated clinical efficacy results in an oral presentation on Friday April 1st, 2011.
The 46th meeting of the European Association for the Study of the Liver.